$33.28
1.89%
Nasdaq, Oct 02, 04:00 pm EDT. Closed.
ISIN
US3371851029
Symbol
TRAX

First Tracks Biotherapeutics Inc Stock price

$33.28
-12.00 26.50% 1M
+20.07 151.93% 6M
+20.61 162.67% YTD
+20.61 162.67% 1Y
+20.61 162.67% 3Y
+20.61 162.67% 5Y
+20.61 162.67% 10Y
+20.61 162.67% 20Y
Nasdaq, Closing price Fri, Oct 02 2026
-0.64 1.89%
ISIN
US3371851029
Symbol
TRAX
Industry

Is First Tracks Biotherapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,120 stocks worldwide.

Key metrics

Basic
Market capitalization
$1.2b
Enterprise Value
$1.0b
Net debt
positive
Cash
$168.0m
Shares outstanding
35.4m
Valuation
P/E
-
P/S | estimate
- | -
EV/Sales | estimate
- | -
EV/FCF | ex SBC
- | -
P/B
7.0
Financial Health
Equity Ratio
87.0%
Return on Equity
-57.8%
ROCE
-
ROIC
-
Debt/Equity
0.0
Financials
Revenue | estimate
- | $0.0
EBITDA
-
EBIT
-
Net Income
-
Free Cash Flow | ex SBC
- | -
Growth
Revenue | estimate
- | -
EBITDA
-
EBIT
-
Net Income
-
Free Cash Flow
-
Margin
Gross
-
EBITDA
-
EBIT
-
Net
-
Free Cash Flow | ex SBC
- | -
More
EPS
-
FCF per Share
-
Short interest
-
Employees
-
Rev per Employee
-

First Tracks Biotherapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a First Tracks Biotherapeutics Inc forecast:

14x Buy
93%
1x Hold
7%

Analyst Opinions

15 Analysts have issued a First Tracks Biotherapeutics Inc forecast:

Buy
93%
Hold
7%

Financial data from First Tracks Biotherapeutics Inc

Jun '26
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 9.29 9.29
40% 40%
-
- Research and Development Expense 26 26
35% 35%
-
-35 -35
24% 24%
-
- Depreciation and Amortization 0.11 0.11
62% 62%
-
EBIT (Operating Income) EBIT -35 -35
24% 24%
-
Net Profit -33 -33
21% 21%
-

In millions USD.

Don't miss a Thing! We will send you all news about First Tracks Biotherapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

First Tracks Biotherapeutics Inc Stock News

Neutral
GlobeNewsWire
●
about 2 months ago
SAN DIEGO, Aug. 12, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases, today reported financial results for the second quarter ended June 30, 2026, and provided a business update.

Company Profile

First Tracks Biotherapeutics, Inc. engages in the research and development of immunology therapeutics for autoimmune and inflammatory diseases. The company is headquartered in San Diego, California and currently employs 104 full-time employees. The company went IPO on 2026-04-06. The firm's clinical-stage pipeline includes Rosnilimab, a selective pathogenic T cell depleter, for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a blood dendritic cell antigen 2 (BDCA2) modulator. Rosnilimab is an IgG1 antibody that directly targets pathogenic T cells, such as activated Tph/Tfh and T effector cells, in the periphery or inflamed tissue. Rosnilimab is designed to selectively deplete pathogenic T cells while sparing non-pathogenic T cells, including naive T cells, to preserve overall immune function and restore immune homeostasis. Its molecules have applicability across a range of autoimmune and inflammatory diseases, including gastroenterology, rheumatology and other areas.

Head office United States
Website www.firsttracksbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today